

Fabian Docagne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8016427/publications.pdf>

Version: 2024-02-01

50
papers

3,598
citations

117625

34
h-index

189892

50
g-index

55
all docs

55
docs citations

55
times ranked

4820
citing authors

#	ARTICLE	IF	CITATIONS
1	Roles of the tissue-type plasminogen activator in immune response. <i>Cellular Immunology</i> , 2022, 371, 104451.	3.0	15
2	PAI-1 production by reactive astrocytes drives tissue dysfibrinolysis in multiple sclerosis models. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	1
3	Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses. <i>Journal of Neuroinflammation</i> , 2021, 18, 52.	7.2	5
4	Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanisms. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2235-2247.	3.8	2
5	Environmental enrichment alleviates the deleterious effects of stress in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095980.	1.0	3
6	Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor. <i>Brain</i> , 2020, 143, 2957-2972.	7.6	39
7	Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	9
8	Nonionotropic Action of Endothelial NMDA Receptors on Blood-Brain Barrier Permeability via Rho/ROCK-Mediated Phosphorylation of Myosin. <i>Journal of Neuroscience</i> , 2020, 40, 1778-1787.	3.6	36
9	HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1081.	4.8	56
10	Reduced spinal cord parenchymal cerebrospinal fluid circulation in experimental autoimmune encephalomyelitis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1258-1265.	4.3	23
11	Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System. <i>Theranostics</i> , 2018, 8, 1195-1212.	10.0	55
12	Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin. <i>Cell Discovery</i> , 2017, 3, 17001.	6.7	37
13	Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 6116-6121.	7.1	43
14	Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re)myelination. <i>Molecular Neurodegeneration</i> , 2017, 12, 20.	10.8	12
15	ADAMTS-4 in oligodendrocytes contributes to myelination with an impact on motor function. <i>Glia</i> , 2017, 65, 1961-1975.	4.9	10
16	Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities. <i>Lancet Neurology</i> , The, 2016, 15, 1089-1102.	10.2	112
17	Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis. <i>Brain</i> , 2016, 139, 2406-2419.	7.6	40
18	The plasminogen activation system in neuroinflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 395-402.	3.8	52

#	ARTICLE	IF	CITATIONS
19	Understanding the Functions of Endogenous and Exogenous Tissue-Type Plasminogen Activator During Stroke. <i>Stroke</i> , 2015, 46, 314-320.	2.0	46
20	Letter by Macrez et al Regarding Article, "Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke". <i>Stroke</i> , 2015, 46, e177-e177.	2.0	0
21	Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System. <i>Current Pharmaceutical Design</i> , 2014, 20, 4707-4722.	1.9	69
22	Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier. <i>Chemical Reviews</i> , 2013, 113, 1877-1903.	47.7	187
23	tPA in the injured central nervous system: different scenarios starring the same actor?. <i>Neuropharmacology</i> , 2012, 62, 749-756.	4.1	46
24	Glutamate Controls tPA Recycling by Astrocytes, Which in Turn Influences Glutamatergic Signals. <i>Journal of Neuroscience</i> , 2012, 32, 5186-5199.	3.6	67
25	Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. <i>NeuroImage</i> , 2012, 63, 760-770.	4.2	64
26	CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. <i>Glia</i> , 2012, 60, 1437-1450.	4.9	113
27	The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 736-749.	4.1	63
28	Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1 receptors. <i>Journal of Neuroinflammation</i> , 2011, 8, 102.	7.2	51
29	Tissue plasminogen activator prevents white matter damage following stroke. <i>Journal of Experimental Medicine</i> , 2011, 208, 1229-1242.	8.5	72
30	Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults. <i>PLoS ONE</i> , 2011, 6, e23690.	2.5	23
31	An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2010, 37, 166-176.	4.4	82
32	Anandamide enhances IL-10 production in activated microglia by targeting CB ₂ receptors: Roles of ERK1/2, JNK, and NF- κ B. <i>Glia</i> , 2010, 58, 135-147.	4.9	149
33	The endocannabinoid system is modulated in response to spinal cord injury in rats. <i>Neurobiology of Disease</i> , 2009, 33, 57-71.	4.4	107
34	A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. <i>Biochemical Pharmacology</i> , 2009, 77, 86-100.	4.4	85
35	Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. <i>Glia</i> , 2009, 57, 1802-1814.	4.9	52
36	Chapter 9 The Endocannabinoid Anandamide. <i>Vitamins and Hormones</i> , 2009, 81, 207-230.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. <i>European Journal of Neuroscience</i> , 2008, 28, 633-641.	2.6	103
38	Therapeutic potential of CB2 targeting in multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 185-195.	3.4	37
39	Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E2. <i>Biochemical Journal</i> , 2008, 409, 761-770.	3.7	40
40	Cannabinoid CB ₁ and CB ₂ Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. <i>Journal of Neuroscience</i> , 2007, 27, 2396-2402.	3.6	243
41	Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis. <i>NeuroImmunoModulation</i> , 2007, 14, 182-187.	1.8	20
42	Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. <i>Molecular and Cellular Neurosciences</i> , 2007, 34, 551-561.	2.2	103
43	The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. <i>Biochemical Pharmacology</i> , 2006, 72, 869-880.	4.4	51
44	Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. <i>European Journal of Neuroscience</i> , 2005, 21, 1205-1214.	2.6	40
45	Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. <i>British Journal of Pharmacology</i> , 2005, 145, 441-448.	5.4	114
46	The Role of Cannabinoid System on Immune Modulation: Therapeutic Implications on CNS Inflammation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 671-675.	2.4	33
47	Smad3-Dependent Induction of Plasminogen Activator Inhibitor-1 in Astrocytes Mediates Neuroprotective Activity of Transforming Growth Factor- β 1 against NMDA-Induced Necrosis. <i>Molecular and Cellular Neurosciences</i> , 2002, 21, 634-644.	2.2	77
48	The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. <i>Nature Medicine</i> , 2001, 7, 59-64.	30.7	678
49	Transforming growth factor- β 1 as a regulator of the serpins/tPA axis in cerebral ischemia. <i>FASEB Journal</i> , 1999, 13, 1315-1324.	0.5	96
50	Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor β 1. <i>FASEB Journal</i> , 1998, 12, 1683-1691.	0.5	115